Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...

Schrödinger Inc.’s stock soared 14% Tuesday to put in on track for its biggest one-day gain in a year, after the company said ...

Qatar is to adopt the Cardio4cities approach – a data-driven cardiovascular population health initiative – and become the ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

The price trend for Novartis (NVS) has been bearish lately and the stock has lost 5.1% over the past two weeks. However, the ...

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

Schrödinger shares rise as they announce a research partnership and licensing agreement with Novartis AG. Schrödinger will ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...

UBS analyst Matthew Weston maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF111.00. According to TipRanks, Weston is ranked #1736 out of 9162 analysts ...

Novartis AG's revenue and core EPS topped analysts' expectations in Q3. Click here to read more on the analysis of NVS stock ...